Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Vegas who wrote (3860)	8/26/2003 3:52:02 PM
From: Crossy	Read Replies (1) \| Respond to of 37387

Vegas, I usually don't use TA but let fundamentals be my guide.. there are a dozen TA systems you could use.. what I see here is quarterly earnings potential of about $0,18-0,25 with the exception of the winter quarter. In total I see EPS generating ability of around $0.70-0.80 per year in a relatively optimistic scenario here. This is pretax but they have plenty of NOLs to utilize .. accretive acquisitons, hinted in the 10Q could further add here.. rgrds CROSSY

To: Vegas who wrote (3860)	8/26/2003 7:38:04 PM
From: Patentlawmeister	Respond to of 37387

re - CREB - the stock was well below 1.00 BEFORE the co. reported .17 eps in the latest quarter, so even though it's up 300% already from the yearly low i wouldn't exactly call it a "chase" play. Based on the MED experience 2 years back (formerly MDFT), it's BB companies with these kind of stats that have the earmarks of early 20-50 baggers. Suppose CREB management makes another accretive acquisition, or they improve efficiencies further, etc., whereby they're making a STEADY .17 or more per quarter? Then where will the stock be trading? Note that MED, now trading at 13.50, earned .31 after dilution for the entire year (and .05 the last quarter according to Yahoo Finance).